Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAST-D: Augmentation and Switching Treatments for MDD
NCT01421342Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Dec 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bupropion and aripiprazole in major depressive disorder (MDD) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Rate of Protocol Remission of Symptoms of Major Depressive Disorder at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
bupropionaripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01421342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421342.